Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

ThromboGenics N.V.. (3/15/18). "Press Release: ThromboGenics Business Update – FY 2017". Leuven.

Organisations Organisation ThromboGenics N.V. (Euronext Brussels: THR)
  Today Oxurion N.V. (Euronext Brussels: OXUR)
  Group Oxurion (Group)
  Organisation 2 Oncurious N.V.
  Group Oxurion (Group)
Products Product Jetrea®
  Product 2 THR-317 (ThromboGenics)
Index term Index term Novartis–ThromboGenics: ocriplasmin, 201203– 201709 commercialisation rights for Jetrea outside US to Alcon €75m upfront + €300m ms TERMINATED 9/17
Persons Person De Haes, Patrik (ThromboGenics 200808– CEO before Roche Diagnostics)
  Person 2 Vangeersdaele, Vinciane (ThromboGenics 201711– CCO before Novartis Ophthalmics)

Record changed: 2018-09-25


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Oxurion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top